PREC BIOLOGICS INC has a total of 34 patent applications. It increased the IP activity by 200.0%. Its first patent ever was published in 2002. It filed its patents most often in United States, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are AXON NEUROSCIENCE SE, GAMAMABS PHARMA and SURFACE ONCOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 18 | |
#2 | EPO (European Patent Office) | 8 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | Brazil | 1 | |
#7 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Therapeutic chemical compounds | |
#5 | Microorganisms | |
#6 | Sugars |
# | Name | Total Patents |
---|---|---|
#1 | Arlen Philip M | 13 |
#2 | Wang Xue-Ping | 12 |
#3 | Tsang Kwong Y | 10 |
#4 | Arlen Myron | 8 |
#5 | Tsang Kwong | 8 |
#6 | Bristol J Andrew | 6 |
#7 | Fantini Massimo | 5 |
#8 | David Justin M | 4 |
#9 | Hollinshead Ariel | 3 |
#10 | Arlen Philip | 3 |
Publication | Filing date | Title |
---|---|---|
BR112020016374A2 | METHODS AND COMPOSITIONS TO DIRECT TREG CELLS | |
CA3083467A1 | Monoclonal antibody neo-201 for the treatment of human carcinomas | |
EP2938633A1 | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer | |
EP2622091A2 | Colon and pancreas cancer peptidomimetics |